Pay-for-Performance Deals
By Business Review Editor
Pharma Deals Review: Vol 2008 Issue 91 (Table of Contents)
Published: 8 Jan-2008
DOI: 10.3833/pdr.v2008.i91.238 ISSN: 1756-7874
Section: General
Fulltext:
Abstract
In October 2007, Janssen-Cilag proposed the UK National Health Service to refund costs for Velcade® (bortezomib) in patients whose tumors do not shrunk sufficiently after a specified treatment period...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS